anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Aeglea BioTherapeutics · pitchdeck

Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides

37 pages · 3 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides

Aeglea BioTherapeutics · 2023-04
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 22 hits
— 0/3 slides
33.3% 1/3 slides 33.3% 1/3 slides 100% 3/3 slides 100% 3/3 slides Solution 5 slides 100% 5/5 slides 100% 5/5 slides · 22 hits
— 0/5 slides
— 0/5 slides
— 0/5 slides
100% 5/5 slides · 7 hits
— 0/5 slides
Evidence and Proof 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides · 4 hits
— 0/2 slides

Slide inventory

37
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, tagline, date, and ticker symbol.front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a list-based structure to categorize updates into clinical programs and corporate status.summarize
Open slide detail
04
The slide uses a Gantt-style chart to represent clinical trial progress.plan_implementation
Open slide detail
05
front_matter
Open slide detail
06
The slide uses a human silhouette to map clinical manifestations to specific body systems.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the patient burden.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number line to show age of diagnosis, followed by key metrics on cliframe_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
Includes a biological process diagram showing intracellular vs plasma metabolism.present_solution
Open slide detailBeat · Solution
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and patient eligibility requirements.plan_implementation
Open slide detailBeat · Solution
11
The chart displays efficacy data for a drug candidate, noting the impact of anti-drug antibodies (ADAs) on the third cohort.show_traction
Open slide detailBeat · Solution
12
show_traction
Open slide detailBeat · Solution
13
ADA stands for Anti-Drug Antibodies.summarize
Open slide detailBeat · Solution
14
transition
Open slide detail
15
The slide uses a timeline-based visual to show disease progression.frame_problem
Open slide detailLoop · Jobs To Be Done
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.establish_context
Open slide detailLoop · Jobs To Be Done
17
The slide presents two distinct clinical metrics: a box plot for arginine levels and a bar chart for patient response rates.show_traction
Open slide detailLoop · Jobs To Be Done
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.show_traction
Open slide detailLoop · Jobs To Be Done
19
The slide uses a heatmap to visualize individual patient outcomes, highlighting clinical improvement vs. worsening.analyze_data
Open slide detailLoop · Jobs To Be Done
20
Clinical trial safety data comparing Pegzilarginase to Placebo.analyze_data
Open slide detailLoop · Jobs To Be Done
21
transition
Open slide detail
22
summarize
Open slide detail
23
Contains company logo, address, and website.front_matter
Open slide detail
24
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.present_solution
Open slide detail
25
Includes a Kaplan-Meier survival curve and a comparative table of clinical outcomes.frame_problem
Open slide detail
26
The chart shows a clear dose-response relationship where the 10.0 mg/kg dose achieves a more significant and sustained reduction in tHcy compared to the 1.0 mg/analyze_data
Open slide detail
27
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to support the clinical hypothesis.analyze_data
Open slide detail
28
Includes histological images of liver tissue and a dot plot for bone mineral density (BMD).show_traction
Open slide detail
29
Data presented includes age, sex, and region for a total N=32.analyze_data
Open slide detail
30
The table displays mean/SD and median/range for Plasma Arginine, GMFM-E, and 2MWT, and counts/percentages for GMFCS levels.analyze_data
Open slide detail
31
Box plot visualization of clinical trial results.show_traction
Open slide detail
32
Includes both continuous mean change data and categorical responder analysis.show_traction
Open slide detail
33
Includes a study design timeline and MCID reference lines for GMFCS levels.show_traction
Open slide detail
34
The slide outlines standard clinical outcome assessments (COAs) for motor function.present_framework
Open slide detail
35
The slide uses a flow diagram to illustrate the randomization process and study timeline.plan_implementation
Open slide detail
36
The table highlights specific clinical response metrics for six individual patients, demonstrating improvements and normalization of mobility scores.show_traction
Open slide detail
37
The slide uses a 2x2 matrix to describe the launch strategy.plan_implementation
Open slide detail